At the same time, HCC cells utilize the anti-oxidative nuclear factor erythroid 2-related factor 2 (NRF2) pathway as protection from oxidative stress-mediated ferroptosis and hence, NRF2 inhibition enhances the anti-cancer activity of sorafenib in vivo [26]. Here, NFE2L2 is linked to hepatocellular carcinoma.